Summary by Moomoo AI
Akeso Biopharma (Cayman) Limited announced that its independently developed PD-1/VEGF dual-specificity tumor immune therapy drug, Envosi, has shown significant efficacy in a Phase III clinical trial for PD-L1 positive non-small cell lung cancer (NSCLC). The trial results were presented at the 2024 World Conference on Lung Cancer (WCLC), demonstrating that Envosi monotherapy, compared to pembrolizumab monotherapy, extended the median progression-free survival (mPFS) by 5.3 months in the overall population, reaching 11.14 months. In addition, Envosi showed good safety performance without a significant increase in the risk of bleeding. Akeso Biopharma's partner, SUMMIT, also plans to conduct the HARMONi-7 study to further evaluate the efficacy of Envosi in first-line treatment of PD-L1 high-expressing metastatic NSCLC. Envosi has already received acceptance of its new indication marketing application by the China National Medical Products Administration and has been included in priority review since August 2024.